ReviewExpert opinion on pharmacotherapy2020
Pharmacotherapeutic management of co-morbid alcohol and opioid use.
Review in Expert opinion on pharmacotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Trial
- Opioids to Treat Chronic Pain in the Older Adult: A Clinical Consensus to Guarantee Safety and Avoid Adverse Events.Drugs & aging · 2026Review
- The Role of the Ventral Tegmental Area in Reward and Addiction: A Comprehensive Review.Neurosciences (Riyadh, Saudi Arabia) · 2026Review
- The Role of Endogenous Beta-Endorphin and Enkephalins in the Crosstalk Between Ethanol and Morphine.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Divergent gene expression patterns in alcohol and opioid use disorders lead to consistent alterations in functional networks within the dorsolateral prefrontal cortex.Translational psychiatry · 2024Article
- Medication-based treatment among rural, primary care patients diagnosed with opioid use disorder and alcohol use disorder.Journal of substance use and addiction treatment · 2024Article
- Divergent gene expression patterns in alcohol and opioid use disorders lead to consistent alterations in functional networks within the Dorsolateral Prefrontal Cortex.bioRxiv : the preprint server for biology · 2024Article
- Concurrent opioid and alcohol withdrawal management.The mental health clinician · 2023Article
- Role of aldosterone and mineralocorticoid receptor (MR) in addiction: A scoping review.Neuroscience and biobehavioral reviews · 2023Article
- Current and emerging pharmacotherapies for opioid dependence treatments in adults: a comprehensive update.Expert opinion on pharmacotherapy · 2022Review
- Positive associations between cannabis and alcohol use polygenic risk scores and phenotypic opioid misuse among African-Americans.PloS one · 2022Article
- Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.Alcoholism, clinical and experimental research · 2021Article
- Elevated customary alcohol consumption attenuates opioid effects.Pharmacology, biochemistry, and behavior · 2021Article
- Potassium Channels and Their Potential Roles in Substance Use Disorders.International journal of molecular sciences · 2021Review
- Drug addiction co-morbidity with alcohol: Neurobiological insights.International review of neurobiology · 2021Review
- BK channels and alcohol tolerance: Insights from studies onMedicine internationalArticle
- Role of Nanomedicine in Transforming Pharmacotherapy for Substance Use Disorder (SUD).Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Opioid use disorder (OUD) and alcohol use disorder (AUD) are two highly prevalent substance-related disorders worldwide. Co-use of the substances is also quite prevalent, yet there are no pharmacological treatment approaches specifically designed to treat co-morbid OUD and AUD. Here, the authors critically summarize OUD, AUD and opioid/alcohol co-use and their current pharmacotherapies for treatment. They also review the mechanisms of action of opioids and alcohol within the brain reward circuitry and discuss potential combined mechanisms of action and resulting neuroadaptations. Pharmacotherapies that aim to treat AUD or OUD that may be beneficial in the treatment of co-use are also highlighted. Preclinical models assessing alcohol and opioid co-use remain sparse. Lasting neuroadaptations in brain reward circuits caused by co-use of alcohol and opioids remains largely understudied. In order to fully understand the neurobiological underpinnings of alcohol and opioid co-use and develop efficacious pharmacotherapies, the preclinical field must expand its current experimental paradigms of 'single drug' use to encompass polysubstance use. Such studies will provide insights on the neural alterations induced by opioid and alcohol co-use, and may help develop novel pharmacotherapies for individuals with co-occurring alcohol and opioid use disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.